Sorrento Releases Positive Topline Results from the Phase I Study Completed in Australia and Preliminary Results from a Phase Ib Study in China with STI-1558, an Oral M(pro) Inhibitor as a Standalone Treatment for COVID-19 without the Need for Ritonavir Boosting
Topline safety and pharmacokinetic (PK) data from the Phase I single ascending dose (SAD)/multiple ascending…
Articul8 launches Bivia to bring domain-specific decision intelligence to enterprise AI agents